The global ESR1 mutated metastatic breast cancer diagnostics market is projected to grow steadily, expanding from USD 63.4 million in 2024 to USD 89.6 million by 2034, representing a year-over-year growth rate of 4.0%. This growth reflects a compound annual growth rate (CAGR) of 3.7% over the forecast period. Demand for ESR1 mutation diagnostics in …